glp-1 agonists and inflammation in Cardiovascular Diseases: Mechanisms, Clinical Evidence, Emerging Therapies Frontiers | GLP-1 receptor agonist

However, when patients stop taking these drugs, they not only regain weight, but, according to a new study, they also incur increased risk of heart attack, stroke and death compared to staying on the medication

GLP-1RAs contribute to improved glycemic control by lowering glycated hemoglobin (HbA1c) and promoting weight loss without causing hypoglycemia, a notable advantage over sulfonylureas and meglitinides

Wilm B, et al

A patient starting a GLP-1RAespecially if they have diabetes or age-related macular degeneration should have an in-person, comprehensive, dilated eye examination either within the 12 months prior to starting therapy or a baseline examination within one month of initiating therapy, according to the report

36,37,38 Successful and durable weight loss with GLP-1 RAs is only possible with continued treatment

By Application Blood sugar management dominated the GLP-1 supplement market, by application, accounting for a share of 39.25% in 2025